CYCCP

Cyclacel Pharmaceuticals, Inc. [CYCCP] Stock Forecast

Q: What is Cyclacel Pharmaceuticals, Inc. stock symbol ?

Cyclacel Pharmaceuticals, Inc. is a US stock, located in Berkeley heights of Nj and trading under the symbol CYCCP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CYCCP Stock Summary

Earnings are expected to fall -100% next year

Does not have any significance market cap ($2.81M)

Profit margins (-63.67%) are lower than the previous year (-53.7%)

CYCCP has less than 1 year of cash runway

In the News

CYCCP Financial details

Company Rating

Neutral

Market Cap

2.81M

Income

-22.62M

Revenue

420K

Book val./share

0.71

Cash/share

3.96

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

12 May 2020

P/E

-1.21

Forward P/E

PEG

0.72

P/S

8.66

P/B

6.89

P/C

4.46

P/FCF

-0.25

Quick Ratio

0.74

Current Ratio

1.38

Debt / Equity

0.06

LT Debt / Equity

0.06

EPS (TTM)

-26.85

EPS next Y

EPS next Q

EPS this Y

-17.75%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

93.75%

EPS Q/Q

-14.66%

SMA20

-5.3%

SMA50

-10.03%

SMA100

138.35%

Inst Own

Inst Trans

ROA

-199%

ROE

-224%

ROC

-6.57%

Gross Margin

Oper. Margin

-7439%

Profit Margin

-6367%

Payout

-1%

Shs Outstand

Shs Float

Target Price

52W Range

5.25-22.2

52W High

-19.77%

52W Low

+253%

RSI

45.1

Rel Volume

0.34

Avg Volume

1.22K

Volume

414

Perf Week

-9.02%

Perf Month

2.32%

Perf Quarter

Perf Half Y

30.74%

Beta

0.571

Volatility

0.64%, 0.79%

Prev Close

-0.56%

Price

17.65

Change

0.86%

CYCCP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0.49
Net income per share	-143.88	-34.86	-31.74	-32.23	-26.51
Operating cash flow per share	-173.64	-32.75	-31.16	-31.67	-18.94
Free cash flow per share	-173.83	-33.15	-31.2	-31.68	-18.94
Cash per share	218.45	137.91	61.44	27.9	3.97
Book value per share	215	137.31	62.62	23.58	0.71
Tangible book value per share	215	137.31	62.62	23.58	0.71
Share holders equity per share	215	137.31	62.62	23.58	0.71
Interest debt per share	21.89	4.36	0.05	-2.89	0.04
Market cap	10.94M	28.38M	34.72M	6.58M	2.27M
Enterprise value	241.41K	-3.97M	-1.81M	-11.66M	-1.07M
P/E ratio	-1.4	-3.36	-1.84	-0.31	-0.1
Price to sales ratio	0	0	0	0	5.41
POCF ratio	-1.16	-3.58	-1.87	-0.32	-0.14
PFCF ratio	-1.16	-3.53	-1.87	-0.32	-0.14
P/B Ratio	0.93	0.85	0.93	0.42	3.74
PTB ratio	0.93	0.85	0.93	0.42	3.74
EV to sales	0	0	0	0	-2.55
Enterprise value over EBITDA	-0.02	0.37	0.08	0.42	0.04
EV to operating cash flow	-0.03	0.5	0.1	0.56	0.07
EV to free cash flow	-0.03	0.49	0.1	0.56	0.07
Earnings yield	-0.72	-0.3	-0.54	-3.22	-9.93
Free cash flow yield	-0.86	-0.28	-0.53	-3.17	-7.1
Debt to equity	0.1	0.03	0	0.01	0.06
Debt to assets	0.08	0.03	0	0	0
Net debt to EBITDA	1.09	3.04	1.59	0.65	0.11
Current ratio	5.79	14.27	7.73	3.3	0.91
Interest coverage	0	0	0	13.79	0
Income quality	1.21	0.94	0.98	0.98	0.71
Dividend Yield	0.02	0.01	0.01	0.03	0.09
Payout ratio	-0.03	-0.02	-0.01	-0.01	-0.01
Sales general and administrative to revenue	0	0	0	0	16
Research and developement to revenue	0	0	0	0	57.07
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0	0	0
Capex to revenue	0	0	0	0	-0.01
Capex to depreciation	-0.5	-4.8	-0.63	-0.22	-0.19
Stock based compensation to revenue	0	0	0	0	3.51
Graham number	834.29	328.19	211.46	130.79	20.63
ROIC	-0.59	-0.26	-0.51	-1.44	-33.01
Return on tangible assets	-0.51	-0.23	-0.44	-0.77	-2.56
Graham Net	176.82	128.76	57.67	11.8	-3.08
Working capital	11.6M	32.98M	35.65M	17.02M	-717K
Tangible asset value	11.7M	33.26M	37.26M	15.51M	607K
Net current asset value	10.41M	31.93M	35.62M	12.42M	-754K
Invested capital	0.1	0.03	0	0.01	0.06
Average receivables	1.42M	1.32M	2.52M	4.68M	4.29M
Average payables	1.8M	702K	1.32M	2.34M	3.05M
Average inventory	656K	693.5K	630.5K	-2.53M	-2.82M
Days sales outstanding	0	0	0	0	2.55K
Days payables outstanding	16.24K	9.38K	17.97K	29.21K	41.72K
Days of inventory on hand	12.83K	12.48K	4.9K	-64.33K	0
Receivables turnover	0	0	0	0	0.14
Payables turnover	0.02	0.04	0.02	0.01	0.01
Inventory turnover	0.03	0.03	0.07	-0.01	0
ROE	-0.67	-0.25	-0.51	-1.37	-37.16
Capex per share	-0.18	-0.4	-0.05	-0.01	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0.45	0.02	0.04
Net income per share	-8.87	-6.94	-6.51	-7.23	-6.17
Operating cash flow per share	-6.18	-8.21	-1.56	-4.79	-4.58
Free cash flow per share	-6.18	-8.21	-1.56	-4.79	-4.58
Cash per share	21.95	13.68	12.15	7.05	3.96
Book value per share	18.55	17.52	11.51	5.16	0.71
Tangible book value per share	18.55	17.52	11.51	5.16	0.71
Share holders equity per share	18.55	17.52	11.51	5.16	0.71
Interest debt per share	0.1	-0.03	0.08	0.06	0.04
Market cap	8.36M	7.15M	7.39M	4.48M	2.28M
Enterprise value	-9.88M	-4.2M	-2.7M	-1.41M	-1.06M
P/E ratio	-0.28	-0.31	-0.34	-0.18	-0.11
Price to sales ratio	0	0	19.82	280.28	73.56
POCF ratio	-1.62	-1.04	-5.67	-1.11	-0.58
PFCF ratio	-1.62	-1.04	-5.67	-1.11	-0.58
P/B Ratio	0.54	0.49	0.77	1.03	3.76
PTB ratio	0.54	0.49	0.77	1.03	3.76
EV to sales	0	0	-7.25	-87.97	-34.22
Enterprise value over EBITDA	1.15	0.58	0.46	0.2	0.18
EV to operating cash flow	1.91	0.61	2.07	0.35	0.27
EV to free cash flow	1.91	0.61	2.07	0.35	0.27
Earnings yield	-0.89	-0.81	-0.74	-1.36	-2.31
Free cash flow yield	-0.62	-0.96	-0.18	-0.9	-1.71
Debt to equity	0.01	0.01	0.01	0.01	0.06
Debt to assets	0	0	0	0	0
Net debt to EBITDA	2.13	1.57	1.73	0.85	0.58
Current ratio	3.3	2.59	2.27	1.38	0.91
Interest coverage	421.19	67.77	0	0	0
Income quality	0.7	1.18	0.24	0.67	0.74
Dividend Yield	0.01	0.01	0.01	0.01	0.02
Payout ratio	-0.01	-0.01	-0.01	-0.01	-0.01
Sales general and administrative to revenue	0	0	4.22	101.56	60.42
Research and developement to revenue	0	0	12.67	327.25	126.13
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	-0.75	0	0	0
Stock based compensation to revenue	0	0	0.96	24.44	10.39
Graham number	60.87	52.31	41.06	28.99	9.93
ROIC	-0.46	-0.4	-0.55	-1.4	-7.32
Return on tangible assets	-0.27	-0.26	-0.33	-0.49	-0.6
Graham Net	9.29	11.04	6.64	-1.58	-3.07
Working capital	17.02M	11.64M	8.55M	3.02M	-717K
Tangible asset value	15.51M	14.64M	9.63M	4.35M	607K
Net current asset value	12.42M	11.56M	8.48M	2.97M	-754K
Invested capital	0.01	0.01	0.01	0.01	0.06
Average receivables	4.84M	6.29M	4.94M	3.08M	3.08M
Average payables	1.77M	2.54M	2.34M	1.87M	2.56M
Average inventory	-2.82M	-2.82M	0	-1.61M	-1.61M
Days sales outstanding	0	0	710.35	18.11K	8.52K
Days payables outstanding	28.81K	28.23K	523.88	20.2K	39.86K
Days of inventory on hand	-63.45K	0	0	-41.39K	0
Receivables turnover	0	0	0.13	0	0.01
Payables turnover	0	0	0.17	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.48	-0.4	-0.57	-1.4	-8.68
Capex per share	0	-0.01	0	0	0

CYCCP Frequently Asked Questions

What is Cyclacel Pharmaceuticals, Inc. stock symbol ?

Cyclacel Pharmaceuticals, Inc. is a US stock , located in Berkeley heights of Nj and trading under the symbol CYCCP

What is Cyclacel Pharmaceuticals, Inc. stock quote today ?

Cyclacel Pharmaceuticals, Inc. stock price is $17.65 today.

Is Cyclacel Pharmaceuticals, Inc. stock public?

Yes, Cyclacel Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 1.22K
Market Capitalization 2.81M
Employee 12
CEO Mr. Spiro George Rombotis
Headquarters Berkeley Heights,NJ,US
IPO Date 2005-11-30
Website https://www.cyclacel.com

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.